Overview

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase I dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics (PK) of GDC-0917 in patients with refractory solid tumors or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.